Provided by:
Penn Medicine
Continuing Medical and Interprofessional Education

Allogeneic Stem Cell Transplantation Case Conference 2025-2026

Allogeneic Stem Cell Transplantation Case Conference 2025-2026 - 11/12/2026
November 12, 2026
1:00 PM - 2:00 PM
PCAM 12 South Conference Romm 12-122 & Virtual

Target Audience
This program has been designed for INTERNAL MEDICINE - Hematology, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - Blood Banking/Transfusion Medicine

Series Educational Objectives
After participating in this regularly scheduled series, participants should be able to:
1 Discuss novel therapies for Graft-versus-host disease (GVHD)
1 Discuss from an interprofessional perspective appropriate candidates for transplant based on many factors including infectious disease risks, comorbidity risks, disease specific risk factors.
1 Describe how to form an outline of new treatment practices that may impact outcomes, and from an interprofessional perspective discuss availabilities of novel clinical trials and outcomes associated with new approaches
2 Describe outcomes after allogeneic stem cell transplantation for patients with refractory AML or advanced MDS.
2 Describe manifestations of immune effector cell toxicities
3 Discuss best practices for long term follow-up and survivorship issues after allogeneic BMT
7 Describe differences and potential risks and benefits associated with different donor choices from an interprofessional perspective with an emphasis on developing a consistent approach to donor selection through systematic evaluation of various options.

Accreditation
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit:

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is approved for **1.00** contact hours UAN Number: JA0000324-0000-26-016-L04-P

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

For more information, please contact
Tamieshia Nixon, Madelyn Fell, Kathryn Stellato
(215) 662-4074, (267) 736-6324, (267) 736-6324
Tamieshia.Nixon@pennmedicine.upenn.edu, madelyn.fell@pennmedicine.upenn.edu, Kathryn.Stellato@pennmedicine.upenn.edu

Check your transcript online at https://upenn.cloud-cme.com

Acknowledgement of Commercial Support*: None

Penn Medicine
Continuing Medical and Interprofessional Education

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Alison Carulli, PharmD	Pharmacy Planner	Nothing to disclose - 10/19/2026
Sarita Chamberlain, MBA	Other Planning Committee Member	Nothing to disclose - 04/15/2026
Noelle V. Frey, MD	Other Planning Committee Member	Consulting Fee-Kite Pharma (Relationship has ended)|Consulting Fee-Sana Biotechnologies (Relationship has ended)|Consulting Fee-Autolus (Relationship has ended) - 08/09/2026
Elizabeth Hexner, MD	Course Director	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Blueprint Medicines|Advisor-Cabaletta Bio Inc|Advisor-Disc Medicine|Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Board of Internal Medicine - 09/09/2026
Alison W Loren, MD	Co-Director, Faculty	Nothing to disclose - 06/24/2026
Selina Luger, MD	Other Planning Committee Member	Consulting Fee-Novartis (Advanced Health Media) (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Astra Zeneca Pharmaceuticals (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Marker|Membership on Advisory Committees or Review Panels, Board Membership, etc.-daichi

		sankyo|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Geron (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-marker therapeutics (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Quetzal - 10/13/2026
Mary Ellen Martin, MD	Other Planning Committee Member	Nothing to disclose - 10/13/2026
Alexander E Perl, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc. (Relationship has ended)|Advisor-Kura Oncology (Relationship has ended)|Advisor-Stemline (Relationship has ended)|Advisor-Johnson & Johnson (Relationship has ended)|Consulting Fee-Astellas|Consulting Fee-Foghorn|Advisor-Genentech (Relationship has ended)|Consulting Fee-Daiichi Sankyo|Consulting Fee-Syndax|Consulting Fee-LLS-BeatAML LLC|Grant or research support-AbbVie, Inc.|Grant or research support-Astellas|Grant or research support-Daiichi Sankyo|Grant or research support-Syndax - 09/23/2026
Linda M Perry, PA-C	Physician Assistant Planner	Paid consultant-Kadmon |Speakers Bureau-Sanofi Genzyme|Paid consultant-Incyte Corporation|Speakers Bureau-Incyte Corporation - 09/15/2026
David L Porter, MD	Course Director	Stocks in any amount, excluding diversified mutual funds of a publicly traded company-Genentech|Honoraria-Novartis (Advanced Health Media) (Relationship has ended)|Honoraria-Bristol-Myers Squibb (Relationship has ended)|Grant or research support-Bristol-Myers Squibb|Honoraria-Gilead Sciences, Inc (Relationship has ended)|Grant or research support-Novartis (Advanced Health Media)|Royalties or Patent Beneficiary-Novartis (Advanced Health Media)|Royalties or Patent Beneficiary-Tmunity (Relationship has ended)|Honoraria-Wiley publishing (Relationship has ended)|Honoraria-Am Society for Transplant and Cell Therapy|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Angiocrine (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Mirror Biologics|Consulting Fee-Sana Biotechnology|Stock options in any amount of a publicly traded or privately owned (non-publicly traded) company-Sana Biotechnologies|Honoraria-Poseida

		(Relationship has ended) - 03/19/2026
Keith Pratz, MD	Other Planning Committee Member	Advisor-AbbVie, Inc.|Advisor-Bristol-Myers Squibb (Relationship has ended)|Advisor-Novartis / Amgen (Relationship has ended)|Advisor-Jazz Pharmaceuticals (Relationship has ended)|Advisor-Astellas (Relationship has ended)|Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended)|Advisor-Roche (Relationship has ended) - 09/30/2026
jacqueline smith, CRNP	Nurse Planner	Nothing to disclose - 10/13/2026
Rose Winchell, MSW	Other Planning Committee Member	Nothing to disclose - 11/02/2026

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected